BRNS · Barinthus Biotherapeutics plc. · Executive Compensation
Market Cap
$30.23M
Shares
40.85M
Volume · Sep 8
378.15K
Avg daily vol (3M)
57.87K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| William Enright | Chief Executive Officer | $2,362,959 |
| Gemma Brown | Chief Financial Officer | $1,106,925 |
| Graham Griffiths | Chief Operating Officer | $896,035 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| William Enright | Chief Executive Officer | $1,811,611 |
| Nadège Pelletier | Chief Scientific Officer | $1,672,999 |
| Graham Griffiths | Chief Operating Officer | $731,060 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| William Enright | Chief Executive Officer | $2,085,399 |
| Meg Marshall | Chief Medical Officer | $922,055 |
| Graham Griffiths | Chief Business Officer | $753,971 |
| Thomas G. Evans | Former Chief Scientific Officer | $752,537 |
| Nadège Pelletier | Chief Scientific Officer | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Meg Marshall | Chief Medical Officer | $3,177,632 |
| William Enright | Chief Executive Officer | $2,739,095 |
| Georgy Egorov | | $2,303,773 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| William Enright | | $3,368,628 |
| Georgy Egorov | | $1,116,865 |
| Meg Marshall | | $684,162 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Douglas Swirsky | principal accounting officer | Appointed | 2026-04-22 |
| Douglas Swirsky | Chief Financial Officer | Appointed | 2026-04-22 |
| Gemma Brown | principal accounting officer | Appointed | 2025-05-07 |
| Gemma Brown | Chief Financial Officer | Terminated | 2025-05-07 |
| Gemma Brown | employment (officer) | Terminated | 2025-01-10 |
| Graham Griffiths | employment (officer) | Terminated | 2025-01-10 |
| Geoffrey Lynn, M.D., Ph.D. | Chief Scientific Officer | Appointed | 2024-11-25 |
| Nadège Pelletier, Ph.D. | Chief Scientific Officer | Resigned | 2024-11-25 |
| Dr. Margaret Marshall | Chief Medical Officer | Retired | 2023-07-26 |
| Chris Ellis | Chief Operating Officer (principal operating officer) | Retired | 2023-04-28 |
| Georgy Egorov | Chief Financial Officer | Terminated | 2022-09-20 |
| Gemma Brown | Chief Financial Officer | Appointed | 2022-09-20 |
Leadership
- William Enright CEO, Board Member
- Robin Wright Chairman
- Douglas Swirsky CFO, Chief Accounting Officer
- Gemma Brown CFO, Chief Accounting Officer
- Graham Griffiths COO
- Alex Hammacher Board Member
- Anne M. Phillips Board Member
- Joseph C. Scheeren Board Member
- Karen T. Dawes Board Member
- Pierre A. Morgon Board Member